Stay updated on CTL019 in Adult ALL: Efficacy & Safety Clinical Trial

Sign up to get notified when there's something new on the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:40:57.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of CTL019 in adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:26.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed participation criteria for the study, specifying eligibility requirements such as health conditions and prior treatments for relapsed or refractory adult B-cell ALL. Previously, it only mentioned that no information was provided regarding study completion and participation criteria.
    Difference
    53%
    Check dated 2024-05-22T21:15:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:58:36.000Z thumbnail image

Stay in the know with updates to CTL019 in Adult ALL: Efficacy & Safety Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page.